All In Biotech

Drug Trial Radar · NCT06749899

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody) Combined With Chemoradiotherapy Versus Chemoradiotherapy Alone in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma:A Randomized, Controlled, Multicenter Phase III Clinical Study.

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

580

Planned (sponsor's estimate)

Start

May 4, 2025

Primary completion

Dec 1, 2028

Study completion Dec 1, 2030

Sponsor

Lead sponsor
Sun Yat-Sen University Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Qilu Pharmaceutical Co., Ltd.
First posted
Dec 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).

Conditions

  • Nasopharyngeal Cancinoma (NPC)
  • Nasopharyngeal Cancer

Interventions

  • QL1706Drug

    QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.

  • GemcitabineDrug

    Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

  • CisplatinDrug

    Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

  • Intensity-modulated radiotherapyRadiation

    Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Failure-free survival (FFS) in intention-to-treat populationTime frame: 3 years
  2. Overall survival (OS) in intention-to-treat populationTime frame: 5 years

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Not yet recruiting

  • First People's Hospital of Foshan

    Foshan, Guangdong, China · Not yet recruiting

  • Guangzhou Panyu Central Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Zhongshan People's Hospital

    Zhongshan, Guangdong, China · Not yet recruiting

  • Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Hubei Province Cancer Hosiptal

    Wuhan, Hubei, China · Not yet recruiting

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The Eye and ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Fujian, Xiamen, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.